An updated version of the 2024/25 National Genomic Test Directory released in England

In July 2024, NHS England issued an updated version of the 2024/25 National Genomic Test Directory, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Three documents were published specifying test codes, clinical indications, target genes, the technology by which tests are available, and eligibility criteria for patients: 

• National Genomic Test Directory for cancer (version 9);
• National Genomic Test Directory for rare and inherited diseases (version 7);
• Rare and inherited disease eligibility criteria (version 7).

A total of 58 new codes (test-indication combinations) were introduced in the Test Directory for cancer. Some examples of the newly added codes are provided below:

• M4.13   Combined Multi-target NGS panel - small variant (EGFR, ALK, BRAF, KRAS, MET exon 14 skipping, ERBB2) and structural variant (ROS1, RET, ALK, NTRK1, NTRK2, NTRK3, MET exon 14 skipping);
• M80.57 WGS Tumour First, in acute myeloid leukemia;
• M80.58 WGS Follow-up Germline, in acute myeloid leukemia;
• M111.7 WGS Tumour First, in T-cell non-Hodgkin lymphoma;
• M111.8 WGS Follow-up Germline, in T-cell non-Hodgkin lymphoma.

Ten new codes (test-indication combinations) were introduced for rare and inherited diseases. Some examples of new codes are provided below:

• R446.1 APOL1 kidney donor testing;
• R210.6 Inherited MMR deficiency (Lynch syndrome).

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.